Oral administration of a casein matrix containing β-casofensin protects the intestinal barrier in two preclinical models of gut diseases. (December 2016)

• Record Type: Journal Article
• Authors: Bessette, Claudine; Henry, Gwénaële; Sekkal, Soraya; Benoit, Bérengère; Bruno, Jérémie; Meugnier, Emmanuelle; Ferrier, Laurent; Théodorou, Vassilia; Léonil, Joelle; Plaisancié, Pascale
• Is Part Of: Journal of functional foods. Volume 27(2016)
• Page Start: 223
• Page End: 235
• Publication Date: 2016-12
• Subjects: Milk-derived bioactive peptide -- β-CN(94–123) -- MUC2 -- Mucus -- Intestinal protection -- Functional food; CT controls -- EC enterochromaffin -- EE enteroendocrine -- ER endoplasmic reticulum -- FD4 FITC–dextran 4 kDa -- GDL gluconolactone -- IBD inflammatory bowel disease -- IBS irritable bowel syndrome -- Id indomethacin -- MPO myeloperoxidase -- MUC2 mucin 2 -- ND nondisturbed -- NMS neonatal maternal separation -- NSAID nonsteroidal anti-inflammatory drug -- PND postnatal day -- Sc subcutaneous -- ZO-1 zonula occludens protein-1 -- 5-HT 5-hydroxytryptamine; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2016.09.007
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: β-Casofensin, a milk bioactive peptide, prevented intestinal hyperpermeability induced by neonatal stress. This effect was accompanied by preservation of the intestinal goblet cells. β-Casofensin also prevented the hyperplasia of enteroendocrine cells induced by neonatal stress. β-Casofensin maintained its effects when administered in a casein matrix. Moreover, a casein matrix with β-casofensin protected against indomethacin-induced enteritis. Abstract: β-Casofensin is a milk-derived bioactive peptide that interacts with intestinal goblet cells. We aimed to determine whether β-casofensin could prevent intestinal dysfunctions induced by neonatal maternal separation (NMS) and whether it retains its protective effects when administered in a casein matrix. We also evaluated whether a casein matrix enriched in β-casofensin protects against intestinal enteritis induced by indomethacin. β-Casofensin abolished NMS-induced jejunal hyperpermeability and prevented the depletion of goblet and Paneth cells induced by NMS. In addition, β-casofensin maintained its effectiveness against NMS-induced intestinal barrier alterations when administered in a casein matrix. A casein matrix containing β-casofensin also reduced intestinal damages induced by indomethacin. A functional food containing β-casofensin may prevent both the deleterious effects of neonatal stress on the intestinal barrier and indomethacin-induced enteritis. These results suggest a promising application of β-casofensin as a gut barrier protector in the context of bioactive foods and clinical nutrition.